Tirzepatide is the active ingredient in Mounjaro and Zepbound, FDA-approved for type 2 diabetes and chronic weight management
doi: 10.3389/fendo.2025.1629488 Received 15 June 2025 Accepted 14 August 2025 Published 10 September 2025 Volume 16 - 2025 Edited by Federico Bertuzzi, Niguarda Ca Granda Hospital, Italy Reviewed by Pratikeswar Panda, Siksha O Anusandhan University, India Basilio Pintaudi, ASST Grande Ospedale Metropolitano Niguarda, Italy Updates Copyright 2025 Castorani, Chiarle, Savastio, Pozzi, Partenope, Pignatiello, Dimarakis, Demichelis, Medina and Rabbone
Ahn (KoBioLabs, Inc.) for cytokine analysis of bacterial isolates in cell lines
The medications weight loss effects reduce fat deposits around the airway, which can decrease airway collapse during sleep and improve OSA symptoms